These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9114522)

  • 1. [Indications and results of treatments of bladder tumors].
    Le Duc A
    Rev Prat; 1997 Feb; 47(4):379-81. PubMed ID: 9114522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
    Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder cancer.
    Clark PE
    Curr Opin Oncol; 2007 May; 19(3):241-7. PubMed ID: 17414643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.
    Parekh DJ; Bochner BH; Dalbagni G
    J Clin Oncol; 2006 Dec; 24(35):5519-27. PubMed ID: 17158537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
    Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
    Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treated natural history of high risk superficial bladder cancer: 15-year outcome.
    Cookson MS; Herr HW; Zhang ZF; Soloway S; Sogani PC; Fair WR
    J Urol; 1997 Jul; 158(1):62-7. PubMed ID: 9186324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F; Schuster F
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis and treatment of superficial bladder cancers].
    Caremel R; Pfister C
    Rev Prat; 2007 Mar; 57(6):621-7. PubMed ID: 17593786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tumors of the bladder in women. Epidemiologic and therapeutic aspects. Apropos of 40 cases].
    Rabii R; el Moussaoui A; Rais H; Joual A; Debbagh A; el Mrini M; Benjelloun S
    Ann Urol (Paris); 1998; 32(3):166-71. PubMed ID: 9657034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
    Gudjónsson S; Adell L; Merdasa F; Olsson R; Larsson B; Davidsson T; Richthoff J; Hagberg G; Grabe M; Bendahl PO; Månsson W; Liedberg F
    Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of superficial tumors of the bladder].
    Patard JJ; Chopin D; Abbou CC
    Cancer Radiother; 1998 Apr; 2 Suppl 1():19s-26s. PubMed ID: 9749073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder cancer.
    Gwynn ES; Clark PE
    Curr Opin Oncol; 2006 May; 18(3):277-83. PubMed ID: 16552241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical management of bladder cancer in 2003.
    Wade M; Seigne JD
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):781-92. PubMed ID: 14686700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
    Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
    J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.